A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion

Starting soon · Phase 2

Conditions studied: Malignant Pleural Effusions (Mpe)

In brief

This study aims to evaluate the efficacy and safety of intrapleural JMKX000197 compared with intrapleural cisplatin in patients with malignant pleural effusion.

Key facts

Study ID

NCT07649369

Run by

Shanghai Jeyou Pharmaceutical Co., Ltd.

People needed

120

Starts

2026-08-17

Expected to finish

2028-08-14

Last updated by the study team

2026-06-16

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with advanced solid tumors diagnosed by histopathology or cytopathology.
• Moderate to large pleural effusions require intervention.
• ECOG performance status: 0 to 2.
• Life expectancy ≥ 3 months
• Adequate organ function.
• The serum pregnancy test of female participants of childbearing potential should be negative within 7 days prior to enrollment and must not be breastfeeding. With a fertile female/male must agree to use medically accepted non-pharmacological contraception during the study and for 6 months after the last dose.

You may not qualify if…

• Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion.
• Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion.
• Known allergies to the study drug or its excipient components.
• Have participated in other clinical trials within 28 days prior to randomization.
• Major surgery within 28 days prior to randomization.
• Central nervous system metastatic disease, leptomeningeal disease, or cord compression.
• Clinical unstable or uncontrolled concomitant cardiovascular, pulmonary, hepatic, renal or seizures diseases.
• Active infections that require systemic treatment.
• Have a history of organ transplantation.
• Any further condition which, in the opinion of the Investigator, the participant is not suitable in the present study.

Where it is running

• Cancer Hospital, Chinese Academy of Medical Sciences — Beijing, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.